Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 647 press releases before 2018
-
AstraZeneca completes commercialisation agreement with Aspen for anaesthetics portfolio
-
AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016
-
AstraZeneca to sell small molecule antibiotics business to Pfizer
-
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
-
AstraZeneca provides update on Phase III trial of Selumetinib in non-small cell lung cancer
-
H1 2016 Results
-
AstraZeneca files first clinical trial application in Moderna messenger RNA collaboration
-
AstraZeneca’s antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia
-
AstraZeneca receives approval in the EU for Qtern (saxagliptin and dapagliflozin) for treatment of Type 2 diabetes
-
Tagrisso met primary endpoint in phase III 2nd-line lung cancer trial
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rob Skelding
Director Global Media Relations (Oncology)
+44 203 749 5821
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
